Skip to main content

My account

Boston Scientific accounts are for healthcare professionals only.

Create an account to access online training and education on EDUCARE, manage your customer profile, and connect with customer support and service teams.

My Boston Scientific account

Access your online applications and manage your customer profile.

Quick Links

Call customer care

Backround image of  blue glowing dots connecting to blue glowing lines

EKOS™ Endovascular System

KNOCOUT PE

Study objective

To understand the impact of the EKOS Endovascular System low-dose, short treatment duration OPTALYSE PE study on various ultrasound-accelerated thrombolysis (USAT) protocols being used as the standard of care in the treatment of acute pulmonary embolism and associated long-term outcomes including quality of life outcomes.

489

489 patients in the prospective cohort

O ICH*

Zero intracerebral hemorrhagic events

23%

23% RV/LV reduction post-procedure


Filename
ekos-knocout-data-summary.pdf
Size
687 KB
Format
application/pdf
Download the data summary

Results

Safety

Major bleeding at 72 hours​

8 (1.6)
Gastrointestinal hemorrhage​2 (0.4)​
Head laceration​1 (0.2)​
Subdural hematoma (pre-existing)​1 (0.2)​
Vascular access site hematoma​4 (0.8)​

Recurrent VTE Within 30 Days

 
Pulmonary Embolism ​2 (0.4)

* 1 preexisting subdural hemorrhage (SDH)

Procedural

Prospective cohort 

Procedural RV/LV ratio by visit graph showing efficacy population in prospective patients.

Efficacy

RV/LV Ratio by Visit on ECHO
Efficacy population in prospective patients

Procedural RV/LV ratio by visit graph showing efficacy population in prospective patients.

Evidence

KNOCOUT shows that contemporary clinical practices are moving to low-dose, short duration OPTALYSE protocols. It adds to the growing evidence that EKOS is effective at treating intermediate-risk and high-risk PE with lower lytic doses and shorter infusion durations compared to other thrombolytic therapies.

Duration and dose by therapy

Bar chart titled Duration and dose by therapy.  EKOS Knocout PE 10.4 hrs


icon of open envelope with letter

Stay up to date

Receive emails on the latest advances, EKOS clinical data and news.

References

1. KonstantinidesS, GeibelA, HeuselG, et al. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N EnglJ Med. 2002;347:1143–1150.

2. Kuo W et al. CHEST 2015; 148(3):667 673.

3. Piazza G et al. A Prospective, Single-Arm, Multicenter Trial of Ultrasound-Facilitated, Catheter-Directed, Low-Dose Fibrinolysis for Acute Massive and Submassive Pulmonary Embolism. The SEATTLE II Study. J Amer Coll Cardiology: Cardiovasc Interventions 2015; 8(10):1382-1392.

4. Sterling KM et al. Prospective Multicenter International Registry of Ultrasound-Facilitated Catheter-Directed Thrombolysis in Intermediate-High and High-Risk Pulmonary Embolism (KNOCOUT PE). Circ Cardiovasc Interv. 2024;17:e013448. doi: 10.1161/CIRCINTERVENTIONS.123.013448

5. TapsonVF, Sterling K, Jones N, et al. A randomized trial of the optimum duration of acoustic pulse thrombolysis procedure in acute intermediate-risk pulmonary embolism: the OPTALYSE PE trial. JACC Cardiovasc Interv. 2018;11:1401-1410. doi: 10.1016/j.jcin.2018.04.008